Tissue Regenix (UK) Today
| TRX Stock | 58.50 1.50 2.50% |
Performance7 of 100
| Odds Of DistressLess than 39
|
Tissue Regenix is trading at 58.50 as of the 3rd of January 2025, a 2.5 percent decrease since the beginning of the trading day. The stock's lowest day price was 56.0. Tissue Regenix has about a 39 percent probability of financial distress in the next few years of operation and did not have a very good performance during the last 90 trading days. The performance scores are derived for the period starting the 11th of October 2023 and ending today, the 3rd of January 2025. Click here to learn more.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | Category Healthcare | Classification Health Care |
Tissue Regenix is entity of United Kingdom. It is traded as Stock on LSE exchange. The company has 71.23 M outstanding shares. More on Tissue Regenix Group
Moving against Tissue Stock
Follow Valuation Profit Patterns Odds of Bankruptcy
Check how we calculate scores
Tissue Stock Highlights
Most reasonable investors view market volatility as an opportunity to invest at a favorable price or to sell short against a bearish trend. Tissue Regenix's investment highlights are automatically generated signals that are significant enough to either complement your investing judgment regarding Tissue Regenix or challenge it. These highlights can help you better understand the position you are entering and avoid costly mistakes.
| CEO Director | Daniel Lee | ||||
| Business Concentration | Biotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, Health Care, Biotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care (View all Sectors) | ||||
Tissue Regenix's financial strength is of vital concern to both outside investors and internal stakeholders. Efficiency and cost control are keys to Tissue Regenix's success, along with its ability to generate sufficient cash flow to pay bills, repay debt, and make a consistent year-to-year profit. | |||||
Debt LevelsTissue Regenix can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Tissue Regenix's financial leverage. It provides some insight into what part of Tissue Regenix's total assets is financed by creditors.
| |||||
Tissue Regenix Group (TRX) is traded on London Exchange in UK and employs 82 people. Tissue Regenix is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Micro-Cap' category with a current market capitalization of 42.74 M. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Tissue Regenix's market, we take the total number of its shares issued and multiply it by Tissue Regenix's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities. Tissue Regenix Group operates under Biotechnology sector and is part of Health Care industry. The entity has 71.23 M outstanding shares.
Tissue Regenix generates positive cash flow from operations, but has no cash available
Check Tissue Regenix Probability Of Bankruptcy
Ownership AllocationTissue Regenix Group shows a total of 71.23 Million outstanding shares. Tissue Regenix Group maintains significant amount of outstanding shares owned by insiders. An insider is usually defined as a CEO, other corporate executive, director, or institutional investor who own at least 10% of the company's outstanding shares. Since such a large part of the company is owned by insiders, it is advisable to analyze if each of these insiders have been buying or selling the stock in recent months. Please note that no matter how many assets the company owns, if the real value of the company is less than the current market value, you may not be able to make money on it.
Check Tissue Ownership Details
Tissue Regenix Group Risk Profiles
Although Tissue Regenix's alpha and beta are two of the key measurements used to evaluate Tissue Regenix's performance over the market, the standard measures of volatility play an important role as well.
| Mean Deviation | 0.9408 | |||
| Semi Deviation | 0.9454 | |||
| Standard Deviation | 1.53 | |||
| Variance | 2.33 |
Tissue Stock Against Markets
Be your own money manager
Our tools can tell you how much better you can do entering a position in Tissue Regenix without increasing your portfolio risk or giving up the expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate risk-adjusted returns of your individual positions relative to your overall portfolio.Did you try this?
Run Latest Portfolios Now
Latest PortfoliosQuick portfolio dashboard that showcases your latest portfolios |
| All Next | Launch Module |
Other Information on Investing in Tissue Stock
Tissue Regenix financial ratios help investors to determine whether Tissue Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Tissue with respect to the benefits of owning Tissue Regenix security.